Vivos Inc. (RDGL)
OTCQB OTCQB Primary Summary
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance
Vivos Therapeutics (NASDAQ:VVOS) announced an expansion of its strategic marketing and distribution alliance with Rebis Health into two additional locations in Colorado. The company said initial data from the partnership showed that patients prefer Vivos CARE as a treatment for obstructive sleep apnea (OSA) nearly two to one over continuous positive airway pressure (CPAP) therapy, the current standard of care treatment.
Vivos Therapeutics announces funding boost
Vivos Therapeutics (NASDAQ:VVOS) has announced definitive agreements for a registered direct offering and concurrent private placement expected to generate up to $6.9 million in gross proceeds The medical device company, which specializes in treatments for sleep-related breathing disorders, said the offering involves the sale of 709,220 shares at $4.935 per share, priced at-the-market under Nasdaq rules, generating gross proceeds of approximately $3.5 million before expenses. Additionally, the company will issue unregistered short-term warrants in a concurrent private placement.
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3
Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses. Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million in the same period last year.
Vivos Inc. (RDGL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vivos Inc. ever had a stock split?
Vivos Inc. Profile
| Health Care Providers & Services Industry | Healthcare Sector | Michael K. Korenko CEO | OTCQB Exchange | 92858K204 CUSIP |
| US Country | 1 Employees | - Last Dividend | 28 Jun 2019 Last Split | - IPO Date |
Overview
Vivos Inc. is a pioneering medical device company focusing on the development of innovative brachytherapy devices for the treatment of non-resectable tumors. Originating in 1994, the company originally operated under the name Advanced Medical Isotope Corporation until rebranding to Vivos Inc. in December 2017. With its headquarters based in Richland, Washington, Vivos Inc. stands out in the radiation oncology field by developing advanced radiopharmaceuticals for both human and veterinary oncology applications. Their commitment to combating cancer through cutting-edge technology is evident in their flagship product, the RadioGel device, among other offerings aimed at improving cancer treatment outcomes.
Products and Services
- RadioGel Device
- IsoPet for Animals
An innovative yttrium-90 based injectable particle-gel designed for the brachytherapy radiation treatment of cancerous tumors. This device represents a significant advancement in the treatment of cancer, providing a highly targeted radiation therapy solution that minimizes damage to surrounding healthy tissues. Its application spans across a variety of tumor types, offering a minimally invasive treatment option for patients with non-resectable tumors.
Expanding the benefits of its brachytherapy technology to veterinary medicine, Vivos Inc.’s IsoPet offers a focused radiation therapy solution for the treatment of solid tumors in animals. This adaptation of their RadioGel technology enables veterinarians to provide state-of-the-art treatment for pet cancer, aligning with the growing demand for advanced veterinary oncology solutions. IsoPet underscores Vivos Inc.’s commitment to enhancing cancer treatment options, further exemplified by its application in both human and veterinary oncology fields.
